Uganda - English - National Drug Authority

johnson&johnson pty ltd - diphenhydramine hydrochloride + ammonium chloride - oral liquid ordinary syrups - 12.5 mg/5ml + 125 mg/5ml

Uganda - English - National Drug Authority

johnson&johnson pty ltd - diphenhydramine hcl + ammonium chloride + codeine phosphate - oral liquid ordinary syrups - 12.5mg/5ml +125mg/5ml +10mg/5ml

Uganda - English - National Drug Authority

johnson&johnson pty ltd - diphenhydramine + paracetamol + pseudoephedrine - oral liquid ordinary syrups - 25mg/20ml + 1g/20ml + 45mg/20ml

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - pimobendan - parenteral liquid/solution/suspension - pimobendan pyridazinone active 0.75 mg/ml - cardiovascular system

Namibia - English - Namibia Medicines Regulatory Council

johnson & johnson medical (pty) ltd - diphenhydramine hcl, paracetamol, pseudoephedrine hcl. - oral liquid - each 20 ml liquid contains diphenhydramine hcl 25,0 mg, paracetamol 1000,0 mg, pseudoephedrine hcl 45,0 mg

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - amlodipine 10 mg - amlodipine besylate/atorvastatin calcium tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. and therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, the atorvastatin component of amlodipine besylate/atorvastatin calcium tablets can be started simultaneously with diet restriction. - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina - reduce the risk of myocardial infarction - reduce the risk of stroke; - reduce the risk of non-fatal myocardial infarction - reduce the risk of fatal

United States - English - NLM (National Library of Medicine)

hikma pharmaceutical - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine besylate 2.5 mg - amlodipine is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. -  chronic stable angina amlodipine is indicated for the treatment of chronic stable angina. amlodipine may be used alone or in combination with other antianginal agents.   -  vasospastic angina (prinzmetal's or variant angina) amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. amlodipine may be used as monotherapy or in combination with other antianginal agents.   -  angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction <40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. amlodipine is contraindicated in patients with known sensitivity to amlodipine. there are no adequate and well-controlled studies in pregnant women. amlodipine should be used during pre

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 5 mg - amlodipine besylate tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. amlodipine besylate tablets are indicated for the symptomatic treatment of chronic stable angina. amlodipine besylate tablets may be used alone or in combination with other antianginal agents. amlodipine besylate tablets are indicated for the treatment of confirmed or suspected vasospastic angina. amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. in patients with recently documented cad by angiography and without heart failure or an ejection fraction < 40%, amlodipine besylate tablets are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. amlodipine besylate tablets are contraindicated in patients with known sensitivity to amlodipine. there are no adequate and well controlled studies in pregnant women. amlodipine should be used dur

United States - English - NLM (National Library of Medicine)

synthon pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - tablet - 2.5 mg - amlodipine besylate is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. amlodipine besylate is indicated for the treatment of chronic stable angina. amlodipine besylate may be used alone or in combination with other antianginal agents. amlodipine besylate is indicated for the treatment of confirmed or suspected vasospastic angina. amlodipine besylate may be used as monotherapy or in combination with other antianginal drugs. amlodipine besylate is contraindicated in patients with known sensitivity to amlodipine.

United States - English - NLM (National Library of Medicine)

st marys medical park pharmacy - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 10 mg - amlodipine besylate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. chronic stable angina amlodipine besylate tablets are indicated for the symptomatic treatment of chronic stable angina. they may be used alone or in combination with other antianginal agents. vasospastic angina (prinzmetal's or variant angina) amlodipine besylate tablets are indicated for the treatment of confirmed or suspected vasospastic angina. they may be used as monotherapy or in combination with other antianginal drugs. angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. amlodipine besylate tablets are contraindicated in patients with known sensitivity to amlodipine.